{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05787574",
            "orgStudyIdInfo": {
                "id": "23-040"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01FD007829",
                    "type": "FDA",
                    "link": "https://reporter.nih.gov/quickSearch/R01FD007829"
                }
            ],
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition",
            "officialTitle": "Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "a-study-of-treatment-of-inflammation-before-stem-cell-transplant-in-people-with-a-primary-immune-regulatory-disorder-pird-and-or-an-autoinflammatory-condition"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2023-03-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-15",
            "studyFirstSubmitQcDate": "2023-03-15",
            "studyFirstPostDateStruct": {
                "date": "2023-03-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Sobi, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells.\n\n\"Funding Source - FDA OOPD\""
        },
        "conditionsModule": {
            "conditions": [
                "Primary Immune Regulatory Disorder",
                "Autoimmune Lymphoproliferative",
                "Immune System Diseases"
            ],
            "keywords": [
                "Stem Cell Transplant",
                "Emapalumab",
                "Fludarabine",
                "Dexamethasone",
                "23-040"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This is a two-stage phase 2 study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 39,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group A: Emapalumab (for isolated Interferongamma mediated disease)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this group will receive emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.",
                    "interventionNames": [
                        "Drug: Emapalumab",
                        "Procedure: Stem Cell Transplant"
                    ]
                },
                {
                    "label": "Group B: Fludarabine and Dexamethasone (for generalized autoinflammation)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this group will receive fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.",
                    "interventionNames": [
                        "Drug: Fludarabine and Dexamethasone",
                        "Procedure: Stem Cell Transplant"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Emapalumab",
                    "description": "Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.",
                    "armGroupLabels": [
                        "Group A: Emapalumab (for isolated Interferongamma mediated disease)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine and Dexamethasone",
                    "description": "Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.",
                    "armGroupLabels": [
                        "Group B: Fludarabine and Dexamethasone (for generalized autoinflammation)"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Stem Cell Transplant",
                    "description": "Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.",
                    "armGroupLabels": [
                        "Group A: Emapalumab (for isolated Interferongamma mediated disease)",
                        "Group B: Fludarabine and Dexamethasone (for generalized autoinflammation)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Engraftment",
                    "description": "is defined as the first of three days of absolute neutrophil count \\>500k/\u00b5L and the first of seven days of platelets \\>20,000/\u00b5L in the absence of transfusional support.",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine Overall Survival (OS)",
                    "description": "the duration of time between HCT and death due to any cause",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients receiving first allo-HCT for the following immunologic conditions:\n* Primary Immune Regulatory Disorder with or without a genetic lesion as defined by the Primary Immune Deficiency Treatment Consortium (PIDTC)\n* Patients with autoinflammatory disorders evidenced by cytokine or inflammation assays with at least 1.5x ULN of measured cytokines and/or an elevated ferritin or ESR \\> 2 ULN\n* For inclusion on the emapalumab group, the lesion must be isolated to the IFN\u03b3 pathway (or mediators thereof) with an elevated CXCL9 \\>1.5 ULN OR sIL2R \\>1.5 ULN (or already controlled on immune modulation, provided that CXCL9 or sIL2R levels were elevated prior to initiation of immune modulation). Inclusion on the Fludarabine/dexamethasone group requires inflammation (as defined above) other than an isolated IFN\u03b3 pathway\n* Able to tolerate cytoreduction (based on adequate organ function as described below)\n* Patients of any age can enroll so long as they meet other inclusion criteria:\n* Adequate organ function is required, defined as follows:\n\n  * Hepatic: Serum bilirubin \u2264 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders related to their PIRD diagnosis are eligible.\n  * Hepatic: AST, ALT, and alkaline phosphatase \\< 2.5 times the upper limit of normal unless thought to be disease-related. Investigator will need to perform clinically indicated evaluations to assess if disease related or intrinsic liver disease. Additional testing may be done if clinically indicated, after the pre-transplant immune prophase and prior to start of conditioning as this will provide additional data to confirm disease related versus intrinsic liver dysfunction.\n  * Renal: serum creatinine \\<1.5x normal for age. If serum creatinine is outside the normal range, then CrCl \\> 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) \\>30% of predicted normal for age.\n  * Normal GFR by Age\n  * Cardiac: LVEF \u2265 50% by MUGA or resting echocardiogram.\n  * Pulmonary: Pulmonary function testing (FEV1 and corrected DLCO) \u2265 50% predicted (pediatric patients unable to complete PFTs will need oxygen saturation as recorded by pulse oximetry of \u226592% on room air).\n* Adequate performance status:\n\n  * Age \u2265 16 years: ECOG \u2264 1 or Karnofsky 70%\n  * Age \\< 16 years: Lansky 70%\n* Each patient must be willing to participate as a research subject and must sign an informed consent form or legal guardian with assent as appropriate.\n\nExclusion Criteria:\n\n* Uncontrolled infection at the time of enrollment.\n* Patients who have undergone previous allo-HCT.\n* Patient seropositivity for HIV I/II and/or HTLV I/II.\n* Females who are pregnant or breastfeeding.\n* Patients unwilling to use contraception during the study period.\n* Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.\n\nDonor Inclusion Criteria:\n\n* Related Donors:\n\n  * 8/8 or 7/8 HLA matched at A, B, C, and DRB1 loci, as tested by DNA analysis.\n  * Haploidentical donors at A, B, C and DRB1 loci, as tested by DNA analysis\n* Unrelated Donors:\n\n  o 8/8 or 7/8 matched at A, B, C, and DRB1 loci, as tested by DNA analysis.\n* Able to provide informed consent for the donation process per institutional standards.\n* Meet standard criteria for donor collection (e.g. National Marrow Donor Program Guidelines or collecting center guidelines as approved by treating physician).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joseph Oved, MD",
                    "role": "CONTACT",
                    "phone": "646-888-3314",
                    "email": "ovedj@mskcc.org"
                },
                {
                    "name": "Roni Tamari, MD",
                    "role": "CONTACT",
                    "phone": "646-608-3738"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Joseph Oved, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Bergen (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Montvale",
                    "state": "New Jersey",
                    "zip": "07645",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.04676,
                        "lon": -74.02292
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        },
                        {
                            "name": "Jaap Jan Boelens, MD, PhD",
                            "role": "CONTACT",
                            "phone": "212-639-3643"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Rockville Centre",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Oved, MD",
                            "role": "CONTACT",
                            "phone": "646-888-3314"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.65871,
                        "lon": -73.64124
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org/mskcc/html/44.cfm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10293",
                    "name": "Inflammation",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "asFound": "Immune System Diseases",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10406",
                    "name": "Interferon-gamma",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}